A Phase 3 interventional study of NaF and Placebo in Caries, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 78 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-01.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to evaluate the effect of fluoride dentifrices on enamel with artificial caries lesions in an in situ model
In situ models represent an acceptable approach for testing the anti-caries potential of fluoride products. This study is to evaluate the effect of fluoride dentifrice containing 1450 parts per million fluoride (ppm F) on enamel with artificial caries lesions in an in situ model. The study toothpaste containing sodium fluoride (NaF) and 0.4% carbopol will be compared to 4 other dentifrices. Comparator toothpastes include NaF toothpaste (1400 ppm F), NaF toothpaste (675 ppm F), sodium monofluorophosphate (NaMFP) and NaF toothpaste (1450 ppm F) and placebo toothpaste (0 ppm F).
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study toothpaste containing 1450 ppm F as NaF and 0.4% carbopol as excipient.
Drug: NaF
Study toothpaste containing 1400 ppm F as NaF
Drug: NaF
Reference toothpaste containing 1000 ppm F as NaMFP and 450 ppm F as NaF
Drug: NaF · Drug: NaMFP
Study toothpaste containing 675 ppm F as NaF
Drug: NaF
Fluoride free placebo toothpaste (0 ppm F)
Drug: Placebo
Fluoride
Also known as: Fluoride
Placebo
Fluoride
Percentage Surface Microhardness Recovery (%SMHR) of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and NaF Toothpaste (1400ppmF)
SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.
Time frame: Baseline to 14 days
Percentage SMHR of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaMFP/NaF Toothpaste (1450ppmF), NaF Toothpaste (675ppmF) and Placebo Toothpaste (0ppmF)
SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.
Time frame: Baseline to 14 days
Percentage SMHR of Demineralized Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste(1450ppmF) and Placebo Toothpaste (0ppmF)
SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.
Time frame: Baseline to 14 days
Enamel Fluoride Uptake (Sound Enamel Specimens)
Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.
Time frame: Baseline to 14 days
Enamel Fluoride Uptake (Demineralized Specimens)
Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.
Time frame: Baseline to 14 days
| Milestone | Sodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F) | NaF Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 11 | 12 | 12 | 11 | 11 |
| Completed | 11 | 11 | 12 | 9 | 10 |
| Not completed | 0 | 1 | 0 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Other reason | 0 | 0 | 0 | 0 | 1 |
| Milestone | Sodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F) | NaF Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 10 | 12 | 10 | 11 | 10 |
| Completed | 10 | 11 | 9 | 10 | 10 |
| Not completed | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 | 1 | 0 |
| Milestone | Sodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F) | NaF Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 9 | 11 | 10 | 10 | 10 |
| Completed | 9 | 11 | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F) | NaF Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 12 | 9 | 10 | 11 | 8 |
| Completed | 12 | 9 | 10 | 11 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F) | NaF Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 8 | 9 | 11 | 10 | 12 |
| Completed | 8 | 9 | 11 | 10 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.
| Percentage SMHR | NaF Toothpaste (1450ppmF) | NaF Toothpaste (1400ppmF) |
|---|---|---|
| Percentage Surface Microhardness Recovery (%SMHR) of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and NaF Toothpaste (1400ppmF) | 28.31 ± 5.54 | 26.32 ± 5.51 |
SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.
| Percentage SMHR | NaF/Carbopol Toothpaste(1450ppmF) | NaF Toothpaste(1400ppmF) | NaMFP/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Percentage SMHR of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaMFP/NaF Toothpaste (1450ppmF), NaF Toothpaste (675ppmF) and Placebo Toothpaste (0ppmF) | 28.31 ± 5.54 | 26.32 ± 5.51 | 26.13 ± 5.49 | 25.52 ± 5.48 | 53.38 ± 5.52 |
SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.
| Percentage SMHR | NaF Toothpaste(1450ppmF) | NaF Toothpaste(1400ppmF) | NaMFP/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Percentage SMHR of Demineralized Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste(1450ppmF) and Placebo Toothpaste (0ppmF) | 34.62 ± 2.82 | 36.06 ± 2.79 | 31.12 ± 2.77 | 27.15 ± 2.77 | 11.10 ± 2.80 |
Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.
| micrograms (μg)*F/centimeters(cm)^2] | NaF Toothpaste (1450ppmF) | NaF Toothpaste (1400ppmF) | NaMFP/ NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Enamel Fluoride Uptake (Sound Enamel Specimens) | 648.06 ± 47.10 | 650.07 ± 46.30 | 541.16 ± 45.91 | 487.14 ± 45.86 | 425.59 ± 46.67 |
Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.
| μg*F/cm^2 | NaF Toothpaste(1450ppmF) | NaF Toothpaste (1400ppmF) | NaMFP/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Enamel Fluoride Uptake (Demineralized Specimens) | 2499.47 ± 133.46 | 2513.37 ± 131.09 | 1923.76 ± 129.91 | 1861.80 ± 129.78 | 686.18 ± 132.20 |
Collected over All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NaF Toothpaste(1450ppmF) | — | 0/50 (0%) | 3/50 (6%) |
| NaF Toothpaste (1400ppmF) | — | 0/52 (0%) | 1/52 (1.9%) |
| NaMFP/NaF Toothpaste (1450ppmF) | — | 0/53 (0%) | 3/53 (5.7%) |
| NaF Toothpaste (675ppmF) | — | 0/53 (0%) | 4/53 (7.5%) |
| Placebo Toothpaste (0ppmF) | — | 0/51 (0%) | 1/51 (2%) |
| Overall | — | 0/57 (0%) | 10/57 (17.5%) |
| Event | NaF Toothpaste(1450ppmF) | NaF Toothpaste (1400ppmF) | NaMFP/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) | Overall |
|---|---|---|---|---|---|---|
| Gingival erythemaGastrointestinal disorders | 3/50 | 1/52 | 3/53 | 4/53 | 1/51 | 10/57 |
| Age, Continuous(years) | All Randomized Participants |
|---|---|
| Mean | 65.5 ± 10.32 |
| Sex: Female, Male(Participants) | All Randomized Participants |
|---|---|
| Female | 34 |
| Male | 23 |
| Region of Enrollment(participants) | All Randomized Participants |
|---|---|
| United States | 57 |
The record gives a start of Apr 2008, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 4 years 11 months after primary completion. A results delay was requested in Sep 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Fluoride